$CLB

Core Laboratories Inc. /DE/

No enriched coverage for $CLB in the last 7 days.

$54K
Bruno Lawrence
0%

Core Laboratories (NYSE:CLB) Misses Q2 CY2026 Sales Expectations

Core Laboratories (NYSE:CLB) reported Q2 CY2026 revenue of $124.6 million, down 4.3% year on year, missing analysts’ sales expectations. Non-GAAP profit was $0.11 per share, 26.9% above consensus. Adjusted EBITDA margin was 11.1% and free cash flow was $3.12 million (2.5% margin). The stock fell 4.2% to $9.45 after the release.

CORE LAB REPORTS SECOND QUARTER 2026 RESULTS

Core Laboratories (NYSE:CLB) reported Q2 2026 revenue of $124.6M, up 2% sequentially but down 4% year over year. Operating income was $9.2M, or $9.4M ex-items. GAAP EPS was $0.13, EPS ex-items $0.11. Free cash flow was $3.1M. The company repurchased 214,712 shares for $2.7M and announced a Q3 dividend.

CLB sentiment & insider activity

Recent CLB coverage spans earnings, market movers and financial news.

In the last 30 days, CLB insiders filed 1 SEC Form 4 transaction — 1 purchase ($54K) and no sales. The most active reporter was Bruno Lawrence, Chairman and CEO, with 1 filing.

What's driving CLB

  • This is a routine insider open-market purchase with no stated 10b5-1 plan, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 4, 2026

  • Revenue miss with EPS beat suggests margin support but weaker top-line momentum, likely keeping near-term sentiment cautious.

    financialcontent.com · Jul 29, 2026

  • Results show sequential improvement but continued geopolitical headwinds, with buyback and a declared Q3 dividend adding capital-return signals.

    prnewswire.com · Jul 29, 2026

  • Q2 results show modest revenue softness but strong ex-items improvement, with margins and FCF providing near-term positioning signals.

    SEC EDGAR 8-K · Jul 29, 2026

  • Move appears driven by oil/geopolitical risk repricing rather than company-specific fundamentals.

    financialcontent.com · Jul 9, 2026

alphai scores every news story that mentions CLB with an AI model for sentiment and relevance, and aggregates insider trades from Core Laboratories Inc. /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CLB

Score

Core Laboratories (NYSE:CLB) Misses Q2 CY2026 Sales Expectations

Core Laboratories (NYSE:CLB) reported Q2 CY2026 revenue of $124.6 million, down 4.3% year on year, missing analysts’ sales expectations. Non-GAAP profit was $0.11 per share, 26.9% above consensus. Adjusted EBITDA margin was 11.1% and free cash flow was $3.12 million (2.5% margin). The stock fell 4.2% to $9.45 after the release.

$CLBMed

CORE LAB REPORTS SECOND QUARTER 2026 RESULTS

Core Laboratories (NYSE:CLB) reported Q2 2026 revenue of $124.6M, up 2% sequentially but down 4% year over year. Operating income was $9.2M, or $9.4M ex-items. GAAP EPS was $0.13, EPS ex-items $0.11. Free cash flow was $3.1M. The company repurchased 214,712 shares for $2.7M and announced a Q3 dividend.

$CLBMed

Core Laboratories Inc. /DE/ (CLB): Results of Operations and Financial Condition

Core Laboratories Inc. /DE/ (CLB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2026 RESULTS: • REVENUE OF $124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR • OPERATING INCOME OF $9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND

Core Laboratories, Excelerate Energy, and Black Stone Minerals Shares Are Falling, What You Need To Know

Core Laboratories (CLB), Excelerate Energy (EE), and Black Stone Minerals (BSM) fell in afternoon trading as WTI crude dropped 2.2% to about $71.88 and Brent slipped below $77. The article links the pullback to profit-taking after U.S. reports of secondary strikes on Iran and Trump saying the ceasefire is over, while tanker traffic through the Strait of Hormuz reportedly continued.

$CLBLow

Core Laboratories Shareholders Back Directors, Auditor and Pay

Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, where investors re-elected two Class I directors, Harvey Klingensmith and Curtis Anastasio, to terms running until 2029. Shareholders also ratified KPMG LLP as the independent registered public accountant for 2026 and supported the company's executive compensation philosophy. This indicates broad support for Core Laboratories' governance and leadership structure, despite an AI analyst's "Neutral" rating on the stock due to weak technicals but partially offset by improved leverage and solid margins.

$COPMed

1 Energy Stock Worth Your Attention and 2 We Question

This article analyzes the energy sector, which has seen significant gains recently, and recommends one stock to buy while advising against two others. ConocoPhillips (COP) is identified as a strong buy due to its market-beating returns, increasing market share, strong revenue growth, and free cash flow margin. Conversely, SLB (SLB) and Core Laboratories (CLB) are noted as stocks to sell due to high extraction costs, low gross margins, slower revenue growth, and unfavorable valuations.

Related tickers